Clinical trial · Interventional
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma
NCT00006473CI-TRIAL-00009040completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase II trial to study the effectiveness of oxaliplatin in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
Conditions
Conditions (17)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Angioimmunoblastic T-cell Lymphoma | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | ALIAS | 0.90 |
| Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | ALIAS | 0.90 |
| Nodal Marginal Zone B-cell Lymphoma | Nodal Marginal Zone Lymphoma | ALIAS | 0.90 |
| Recurrent Adult Burkitt Lymphoma | Adult Burkitt Lymphoma | CURATED_BROADER | 0.78 |
| Recurrent Adult Diffuse Large Cell Lymphoma | — | UNRESOLVED | — |
| Recurrent Adult Diffuse Mixed Cell Lymphoma | — | UNRESOLVED | — |
| Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Non-Hodgkin Lymphoma | CURATED_BROADER | 0.78 |
| Recurrent Adult Immunoblastic Large Cell Lymphoma | Adult Immunoblastic Lymphoma |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| oxaliplatin | Drug | Oxaliplatin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment (oxaliplatin)
- description
- Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
- interventionNames
- Drug: oxaliplatin
Primary outcomes (1)
- measure
- Response rate
- timeFrame
- Up to 6 years
- description
- Using a Simon's two-stage model.
Secondary outcomes (1)
- measure
- Duration of response
- timeFrame
- Up to 6 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:
* Histologically or cytologically confirmed recurrent or refractory non-Hodgkin's lymphoma (NHL) of any histologic subtype
* Indolent
* Follicular small cleaved cell
* Follicular mixed cell
* Small lymphocytic
* Mucosa-associated lymphoid tissue (MALT)
* Monocytoid B-cell
* Waldenstrom's macroglobulinemia
* Aggressive
* Follicular large cell
* Diffuse large cell
* Immunoblastic
* Mantle cell
* Ki-1+ NHL
* Peripheral T-cell
* Angiocentric and angioimmunoblastic
* Transformed lymphoma
* Bidimensionally measurable disease
* No more than 3 prior treatment regimens as follows:
* Primary radiotherapy is 1 regimen
* Combined therapy with radiotherapy and chemotherapy is 1 regimen
* Alternating therapy is 1 regimen
* No known brain metastases
* Performance status - ECOG 0-2
* Performance status - Karnofsky 50-100%
* WBC count at least 3,000/mm\^3
* Absolute neutrophil count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3
* Bilirubin normal
* SGOT/SGPT no greater than 2.5 times upper limit of normal
* Creatinine normal
* Creatinine clearance at least 60 mL/min
* No symptomatic congestive heart failure
* No unstable angina pectoris
* No cardiac arrhythmia
* No neuropathy greater than grade 1
* No history of allergy to platinum compounds or antiemetics
* No uncontrolled illness
* No active infection
* Not pregnant or nursing
* Fertile patients must use effective contraception
* No concurrent colony-stimulating factors during first course of therapy
* At least 4 weeks since prior chemotherapy
* At least 4 weeks since prior radiotherapy
* No other concurrent investigational drugs
* No concurrent antiretroviral therapy for HIV-positive patientsReferences
Publications (0)
Data not yet available
No reference posted for this study.